Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 24, 2020

Primary Completion Date

December 1, 2023

Study Completion Date

October 7, 2024

Conditions
Metastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal AdenocarcinomaStage III Colon Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIA Colon Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIA Rectal Cancer AJCC v8Stage IIIB Colon Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIIC Colon Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IIIC Rectal Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Rectal Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVA Rectal Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVB Rectal Cancer AJCC v8Stage IVC Colon Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Stage IVC Rectal Cancer AJCC v8Unresectable Colon AdenocarcinomaUnresectable Colorectal CarcinomaUnresectable Rectal Adenocarcinoma
Interventions
BIOLOGICAL

Panitumumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Regorafenib

Given PO

DRUG

Trifluridine and Tipiracil Hydrochloride

Given PO

Trial Locations (18)

15212

Allegheny General Hospital, Pittsburgh

20007

MedStar Georgetown University Hospital, Washington D.C.

20010

MedStar Washington Hospital Center, Washington D.C.

27710

Duke University Medical Center, Durham

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

53226

Aurora Cancer Care-Milwaukee West, Wauwatosa

55905

Mayo Clinic in Rochester, Rochester

60637

University of Chicago Comprehensive Cancer Center, Chicago

77030

M D Anderson Cancer Center, Houston

85259

Mayo Clinic in Arizona, Scottsdale

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

90048

Cedars Sinai Medical Center, Los Angeles

92093

UC San Diego Moores Cancer Center, La Jolla

32224-9980

Mayo Clinic in Florida, Jacksonville

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER

NCT03992456 - Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | Biotech Hunter | Biotech Hunter